Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2024-03-19 Regulatory Filings
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
INOVIQ expands exosome IP 2 pages 218.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 20 March 2024 from INOVIQ Limited. It announces the filing of a new Australian Provisional Patent Application related to their EXO-ACE technology for exosome isolation. The content focuses on intellectual property and technology development rather than financial results, management changes, or regulatory filings. The document is relatively short (3761 characters) and is clearly an announcement of a patent filing, not a financial report or detailed regulatory filing. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as it is a regulatory announcement that does not fit into more specific categories like financial reports, management changes, or capital updates.
2024-03-19 English
Exosomes for non-invasive pre-natal testing 1 page
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from INOVIQ Limited dated 19 March 2024. It announces the publication of a scientific paper co-authored by the company's Chief Scientific Officer related to exosome technology for non-invasive prenatal testing. The content focuses on scientific and technological developments and does not contain financial data, regulatory filings, or corporate governance information. It is not a report, earnings release, or management discussion. The document is a corporate announcement about a scientific publication and technology update, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-03-18 English
Appendix 4D and FY24 Half Year Financial Report 20 pages 2.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Financial Report for the Half-Year Ended 31 December 2023' and contains detailed financial statements such as consolidated statements of comprehensive income, financial position, cash flows, and changes in equity. It includes a review of operations, results of operations, principal activities, commercial updates, research and development progress, and corporate changes. The report is for a half-year period ending 31 December 2023, which matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, it fits the classification of an Interim / Quarterly Report (IR). H1 2024
2024-02-22 English
Trading Halt 2 pages 294.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from INOVIQ Ltd regarding a trading halt requested under ASX listing rule 17.1. It states that the trading halt is pending the release of an announcement related to the results of a Breast Cancer Monitoring Study. The document is short (2731 characters) and does not contain any financial data, report content, or detailed analysis. It is clearly an announcement about a trading halt and an upcoming announcement, not the announcement or report itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-02-21 English
INOVIQ detects 19% more breast cancers than leading test 3 pages 266.9KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 22 February 2024 from INOVIQ Limited about the successful completion of a breast cancer study and the performance of their SubB2M/CA15-3 test. It discusses clinical validation results, study details, next steps for commercialization, and background information about the technology and breast cancer monitoring. The document is a company announcement of study results and future plans, not a full financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial analysis. It is not a report publication announcement since it contains substantive information about the study results and company plans. The content fits best as a Capital/Financing Update (CAP) because it relates to a significant development that could impact the company's commercial prospects and capital strategy, aimed at attracting partners and revenue generation. Therefore, the classification is CAP with high confidence.
2024-02-21 English
Appendix 4C and Quarterly Activities Report - December 2023 11 pages 584.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C & QUARTERLY BUSINESS UPDATE Period Ended 31 December 2023' and contains detailed financial and operational information for the quarter ended 31 December 2023. It includes cash balances, R&D progress, commercial updates, and corporate updates including board changes. The length is about 15,000 characters, indicating a substantive report rather than a brief announcement. Appendix 4C is a standard quarterly cash flow report required by the ASX for listed companies, and the content aligns with a quarterly report including financial data and business updates. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2024-01-30 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.